Open AccessP768: GUADECITABINE (SGI‐110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY.
Author(s) -
GarciaManero G.,
Bart S.,
McCloskey J. K.,
Fenaux P.,
Selleslag D.,
Reda G.,
Valcárcel D.,
Santini V.,
Mayer J.,
Xicoy B.,
Yamaguchi H.,
Lübbert M.,
Miyazaki Y.,
Keer H.,
Hao Y.,
Azab M.,
Döhner H.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845956.26644.d0
Subject(s) - medicine , chronic myelomonocytic leukemia , international prognostic scoring system , cytarabine , decitabine , neutropenia , oncology , hazard ratio , febrile neutropenia , gastroenterology , myelodysplastic syndromes , leukemia , chemotherapy , bone marrow , confidence interval , biology , biochemistry , gene expression , dna methylation , gene